Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central Precocious Puberty

Table 5

Characteristics of patients with and without HPG axis suppression (mean ± SD) (range).

Characteristic	HPG axis
	Suppressed ()	Nonsuppressed ()
Chronological age (years)	7.8 ± 1.4 (4.3–9.9)	8.6 ± 1.0 (7.0–10.1)	0.32
Bone age (years)	9.3 ± 2.0 (4.1–11.1)	10.6 ± 1.4 (7.8–12.0)	0.16
BMI SDS	0.8 ± 0.9 (−1.4–1.6)	0.9 ± 0.8 (−1.0–3.3)	0.95
Basal LH (mIU/mL)	1.0 ± 1.2 (0.07–4.6)	2.2 ± 3.3 (0.1–10.4)	0.005
Peak LH (mIU/mL)	9.0 ± 8.9 (3.9–48.8)	11.1 ± 10.6 (5.6–27.1)	0.44
E2 (pg/mL)	26.7 ± 12.9 (3.8–58.5)	32.9 ± 24.0 (7.0–68.7)	0.00
Leuprolide acetate dose (mg/kg/28 days)	0.13 ± 0.14 (0.04–1.12)	0.11 ± 0.02 (0.09–0.17)	0.47

BMI: body mass index; SDS: standard deviation score.